近日，国产创新药企海外商务拓展（BD）合作持续升温，先为达、前沿生物、和铂医药等多家公司相 继披露重磅海外授权协议。从小核酸药物到肿瘤免疫疗法，从产品授权到平台合作，国内创新药领域正 与全球药企深度对接。业内人士表示，密集落地的国际合作不仅为企业带来充裕现金流、助力研发推 进，更标志着我国创新药产业正从单一产品授权向技术输出、平台共建、全球并跑转型，核心赛道全球 化价值持续兑现。 国产创新药企达成多个海外授权合作，将为公司的研发推进和国际化布局等方面带来助力。 前沿生物表示，公司与GSK达成的授权合作，将为公司带来首付款及后续里程碑付款，有利于改善现金 流、优化财务结构，为核心管线研发与技术平台升级提供资金支持。同时，协议中基于合作产品全球净 销售额的分级特许权使用费安排，形成潜在长期收入来源，持续为全体股东创造价值。此外，此次双方 达成合作，体现了公司小核酸药物研发技术与平台价值获得国际认可。未来公司将借助GSK全球临床开 发及商业化资源，加速推进管线国际化价值转化，为后续产品商业化及拓展全球合作奠定基础。 多赛道合作升温 2月24日，先为达与辉瑞中国宣布，双方就新一代偏向型GLP-1受体激动剂埃诺格鲁肽注 ...

Core Viewpoint - The dual-driven logic of "manufacturing advantages + technological innovation" remains solid, and current adjustments provide opportunities for long-term investment [1]. Group 1: Market Outlook for 2025 - The market in 2025 is divided into three phases: - The first phase from post-Spring Festival to April focuses on technology revaluation, driven by the international recognition of the DS model, with strong performances from Hong Kong internet giants and A-share tech companies [5]. - The second phase from May to September highlights accelerated AI capital expenditure and overseas expansion trends, with record-breaking collaborations in innovative drugs and enhanced competitiveness in the energy storage sector driving related stocks up [5]. - The third phase in the fourth quarter shifts towards expectations of PPI recovery due to "anti-involution" policies, benefiting cyclical sectors like chemicals [5]. - The non-ferrous metals industry is a consistent highlight throughout the year, with precious metals performing strongly in a weak dollar environment, leading to increases in industrial metals like copper and silver [5]. Group 2: Investment Opportunities for 2026 - Four key industrial tracks are identified for investment based on the "14th Five-Year Plan": - The AI industry remains central, with a focus on computing power investment as domestic internet companies are expected to significantly increase capital expenditure, benefiting the domestic computing power supply chain [6]. - The overseas expansion of the renewable energy sector, particularly in energy storage and electric vehicles, continues to be promising due to declining lithium battery costs and global energy transition demands [6]. - The commercial aerospace sector is entering an acceleration phase, supported by policy and industry resonance, with significant satellite reserves laid out for industry development [6]. - The internationalization of innovative drugs is progressing, with Chinese companies moving from licensing to direct overseas expansion, showcasing competitive R&D efficiency in large molecule drugs [6]. Group 3: Strategies for Market Volatility - Recent market volatility is attributed to rapid price increases raising demand concerns and emotional disturbances from uncertain events. A strategy of "not chasing high prices, focusing on valuation, and looking long-term" is recommended [7]. - For high-priced assets, careful evaluation of the potential for exceeding performance expectations is necessary, while solid companies with growth potential present opportunities during short-term adjustments [7]. - In managing product portfolios, dynamic adjustments are made through in-depth industry research, tracking changes in competitive landscapes, and timely adjustments to overvalued assets while focusing on undervalued companies with significant growth potential [7]. Group 4: Investment Strategy for the Year of the Horse - The overall market outlook for 2026 is optimistic, with the capital market remaining in a favorable environment. Continuous technological advancements and enhanced competitiveness in high-end manufacturing are expected to support corporate profitability and market stability [8]. - The market is anticipated to trend upward with fluctuations, necessitating a focus on rhythm and structural opportunities. Identifying certainty amid volatility through in-depth research and patient holding is expected to yield good returns [8].

Core Viewpoint - The A-share market is experiencing a strong upward trend, particularly in the innovative drug sector, with significant gains in the ChiNext Innovative Drug ETF [1][3]. Group 1: Market Performance - As of 11:08 on February 10, the ChiNext Innovative Drug ETF (589120) surged by 2%, marking a potential two-day consecutive rise [1]. - Major component stocks of the ETF, such as Rongchang Biopharma and Baili Tianheng, saw increases exceeding 5%, while others like Baijie Shenzhou rose over 4% [3]. Group 2: Key Component Stocks - The top ten component stocks of the ChiNext Innovative Drug ETF include: - J-Z**KD with a 4.04% increase and an estimated weight of 10.43% - Baili Tianheng with a 5.10% increase and an estimated weight of 7.89% - Rongchang Biopharma with a 5.51% increase and an estimated weight of 6.35% [4]. Group 3: Industry Developments - Innovent Biologics announced the approval of its ICP-538, a VAV1 molecular glue degrader, for clinical research, marking it as the first of its kind in China and the second globally [4]. - Baili Tianheng's recent shareholder meeting approved significant resolutions, including the issuance of debt financing tools and extending the validity of H-share issuance [5]. Group 4: Strategic Collaborations - Innovent Biologics entered a strategic partnership with Eli Lilly to advance the global development of innovative drugs in oncology and immunology, receiving an upfront payment of $350 million and potential milestone payments totaling up to $8.5 billion [5]. Group 5: Industry Growth and Trends - The Chinese innovative drug sector is transitioning from "pipeline expectations" to "performance realization," with over 70% of companies projected to achieve revenue growth by 2025 [8]. - The total value of License-out transactions for Chinese innovative drugs skyrocketed from $2.562 billion in 2017 to an estimated $140.274 billion by 2025, indicating a significant increase in global recognition [6]. Group 6: Investment Opportunities - Three key investment themes for 2026 in the innovative drug sector include: 1. Accelerated BD (Business Development) overseas, focusing on ADC, dual antibodies, and GLP-1RA [9]. 2. Policy support for innovative drug development, enhancing commercialization opportunities [9]. 3. Monitoring critical clinical data and commercialization milestones for new drugs [10].

开源证券指出，中国创新药正经历从"规模积累"走向"价值释放"的国际化跨越，并持续迎来从"管线预 期"转向"业绩兑现"的商业化收获期。创新药板块已回调近两个季度，长期看，较多优质标的估值性价 比明显，当前位置建议加大关注。 湘财证券研报表示，站在当前时点来看，医药行业受医保控费影响的预期已充分反映，多层次的支付体 系正在建立，医疗需求的刚性将共同推动行业企稳回升，建议关注高成长及预期改善两大方向。 低位埋伏港股医药机遇，借道ETF效率更高，高弹性，T+0。港股通创新药ETF（520880）及其场外联 接基金（025221），100%布局创新药研发类公司，前十大权重股占比超73%，龙头属性突出。港股通 医疗ETF华宝（159137），锚定医疗创新，囊括脑机接口、AI医疗、互联网药店等热点概念，同时覆盖 创新药全产业链龙头。 2月份以来，港股医药、医疗以一波强势连阳行情，持续修复失地。热门ETF方面，2月10日，港股通创 新药ETF（520880）、港股通医疗ETF（159137）早盘悉数涨逾2%，其中，港股通创新药ETF （520880）涨幅更是逼近3%。值得一提的是，自2月份以来的7个交易日，上述2只ETF双双 ...

2月9日，港股市场全面反弹，港股医药板块延续修复行情。 信达生物拿下88.5亿美元BD大单，无意外全天领涨，最高涨至8.55%，收涨7.42%，龙头股大受提振， 百济神州涨超3%，石药集团、中国生物制药、三生制药集体跟涨。 100%创新药研发标的——港股通创新药ETF（520880）高开后上探2.75%，收涨1.77%成功连阳，一并 站上10日均线，全天成交3.81亿元。 2月8日晚，信达生物公告，公司与礼来制药达成战略合作，携手推进肿瘤及免疫领域创新药物的全球研 发进程。信达将获3.5亿美元首付款，最高可获85亿美元里程碑付款及大中华区以外净销售额梯度分 成。 2025年中国创新药License-out总交易规模达到创纪录的1357亿美元，2026年开年以来重磅合作频出，除 信达外，1月份石药-阿斯利康（185亿美元）、荣昌-艾伯维（56亿美元）两笔超级BD均充分验证国产 创新药管线的全球价值。 开源证券指出，中国创新药正经历从"规模积累"走向"价值释放"的国际化跨越，并持续迎来从"管线预 期"转向"业绩兑现"的商业化收获期。创新药板块已回调近两个季度，长期看，较多优质标的估值性价 比明显，当前位置建议加大 ...

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The Chinese innovative pharmaceutical industry is entering a new phase of development characterized by dual breakthroughs in commercialization and internationalization, with significant growth in License-out transactions from $2.562 billion in 2017 to $140.274 billion in 2025 [5][15] - The industry is transitioning from a phase of pipeline expectations to one of performance realization, with over 70% of companies achieving positive revenue growth in 2025 [6][23] - The innovative drug sector has seen a strong performance in early 2026, with the pharmaceutical and biological sector rising by 0.14%, outperforming the CSI 300 index by 1.47 percentage points [7][29] Summary by Sections Section 1: Breakthroughs in Commercialization and Internationalization - The period from 2017 to 2026 is crucial for the recognition of Chinese pharmaceutical companies in the global market, with a notable increase in License-out transactions [5][15] - In early 2026, significant deals were made, including a $12 billion upfront payment from CSPC to AstraZeneca, indicating the growing international competitiveness of Chinese innovative drugs [16][17] Section 2: Performance of the Pharmaceutical Sector - The pharmaceutical sector has shown robust growth, with companies like BeiGene reporting revenues exceeding 36 billion yuan, reflecting strong commercialization capabilities [6][23] - The overall industry is moving towards profitability, with companies like Innovent Biologics and Rongchang Biopharma achieving breakeven for the first time [6][23] Section 3: Market Trends and Subsector Performance - In the first week of February 2026, the Chinese pharmaceutical sector saw a 0.14% increase, with traditional Chinese medicine leading the gains at 2.56% [7][31] - The medical research outsourcing sector also performed well, increasing by 1.99%, while other subsectors like biological products and vaccines experienced declines [7][31][35]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The Chinese innovative pharmaceutical industry is entering a new phase of development characterized by dual breakthroughs in commercialization and internationalization, with significant increases in License-out transaction values from $2.562 billion in 2017 to $140.274 billion in 2025 [5][15] - The industry is transitioning from a phase of pipeline expectations to one of performance realization, with over 70% of companies achieving positive revenue growth in 2025 [6][23] - The innovative drug sector has seen a strong performance in the first week of February 2026, with a 0.14% increase, outperforming the CSI 300 index by 1.47 percentage points [7][29] Summary by Sections Section 1: Breakthroughs in Commercialization and Internationalization - The period from 2017 to 2026 is crucial for the recognition of Chinese pharmaceutical companies in the global market, with a notable increase in License-out transactions [5][15] - In 2026, the upfront payment for License-out transactions has already exceeded 39% of the total for 2025, indicating improved quality and competitiveness of Chinese innovative drug pipelines [5][15][16] Section 2: Performance of the Pharmaceutical Sector - The innovative drug sector is experiencing rapid revenue growth, with companies like BeiGene achieving over 36 billion yuan in revenue, showcasing strong commercialization capabilities [6][23] - Major companies such as Innovent Biologics and Rongchang Biopharma have maintained robust growth due to their core products, with some companies achieving profitability for the first time [6][23][24] Section 3: Market Trends and Subsector Performance - In the first week of February 2026, the traditional Chinese medicine sector saw the highest increase at 2.56%, while other biopharmaceutical sectors experienced declines [7][31] - The medical research outsourcing sector also performed well, with a 1.99% increase, indicating a positive trend in the pharmaceutical industry overall [7][31][35]

Core Insights - The Chinese biopharmaceutical industry is showing signs of recovery in 2025, with increased license-out transactions, a rebound in primary market financing, and the return of cornerstone investors in Hong Kong biotech IPOs, suggesting a shift from a prolonged downturn to a more normalized state [1][2][4] Group 1: Market Recovery and Trends - The market is transitioning from an "extreme compression" phase to a "relatively normal" state, indicating a quality recovery rather than a full-blown boom [2][4] - The overall pharmaceutical industry saw a 16.72% increase from early 2025 to November, outperforming the CSI 300 index by 1.68 percentage points, driven by breakthroughs in innovative drugs [2][3] - License-out transactions in the innovative drug sector reached $93.7 billion in the first three quarters of 2025, a 64% increase year-on-year, surpassing the total financing amount in the primary market for the first time [3][4] Group 2: Structural Changes and Investment Logic - The core driving forces behind the industry's progress are structural changes rather than short-term stimuli, with a focus on rational project selection and differentiation in product pipelines [2][5] - Investors are increasingly prioritizing clinical data certainty, product differentiation, and global commercialization potential over chasing trends [2][4] - The competitive edge of Chinese innovative drugs has significantly improved, leading to increased cross-border licensing collaborations and the emergence of new cross-border companies [4][5] Group 3: Challenges and Future Indicators - Despite positive trends, challenges such as global interest rate changes, geopolitical uncertainties, and ongoing pressures on domestic healthcare payments remain [4][5] - Key indicators for assessing the sustainability of the recovery include the continued occurrence of high-quality license-out transactions and the ability of Hong Kong to nurture companies with solid data and commercialization capabilities [5][12] Group 4: Global Integration and Market Dynamics - The integration of Chinese innovative drugs into the global pharmaceutical ecosystem is evident, with cross-border collaborations becoming crucial for value realization [11][12] - The return of overseas investors to Hong Kong biotech IPOs reflects a long-term rebuilding of confidence, contingent on companies having globally competitive product pipelines and clear clinical data timelines [11][12] - The differentiation in market dynamics necessitates careful selection of IPO venues based on pipeline stages, funding needs, and adaptability to market rules [12][13] Group 5: Strategic Considerations for Biotech Companies - For small and medium-sized biotech firms, balancing global R&D and commercialization with solidifying the domestic market is a critical challenge [13][14] - A phased globalization approach is recommended, where early R&D aligns with international standards while domestic commercialization focuses on core areas to validate product value [13][14] - The industry's evolution emphasizes quality, differentiation, and global capability, with the 2025 recovery seen as a return to normalcy after a period of structural advantage accumulation [14]

Market Performance - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index increased by 0.5% at midday, while the Hang Seng Hong Kong Stock Connect Innovative Drug Index rose by 0.3%. The CSI Biotechnology Theme Index and the CSI 300 Pharmaceutical and Health Index both saw a 0.1% increase, whereas the CSI Innovative Drug Industry Index declined by 0.2% [1]. Company Developments - Recently, CloudTop New Medicine announced that the U.S. FDA has approved its cardiovascular product, Lurepirdine injection, for lowering low-density lipoprotein cholesterol levels in patients with hypercholesterolemia. The company plans to submit a listing application in the Greater China region in the first half of 2026, which is expected to boost market confidence in the internationalization prospects of innovative drugs [1].

Core Viewpoint - The launch of the Chinese Drug Price Registration System (referred to as "Drug Registration System") is expected to accelerate the internationalization of China's innovative drugs by providing a global, authoritative, standardized, and transparent market price registration platform [1][2]. Group 1: Overview of the Drug Registration System - The Drug Registration System is a national-level price registration platform independent of the medical insurance network, offering services such as price registration, price inquiry, price comparison, and notarization for drug marketing authorization holders [1]. - Pharmaceutical companies can autonomously declare and register drug prices based on their development needs, taking responsibility for the authenticity of the submitted information, while the operating unit only processes registration applications without intervening in pricing [1]. Group 2: Impact on the Pharmaceutical Industry - The establishment of the Drug Registration System is seen as a key measure to address the structural shortcomings in the pricing system, which has become a core bottleneck for companies seeking to internationalize [2]. - The platform aims to create a "one drug, one file" database covering innovative drugs and other registered varieties, providing authoritative support for companies to establish a consistent pricing system in domestic and international markets [2]. - Analysts believe that the Drug Registration System will promote the healthy development of China's pharmaceutical innovation ecosystem and facilitate high-quality internationalization, presenting long-term investment opportunities in the innovative drug sector [2].